Capricor Therapeutics to Present ALLSTAR Phase I Trial Data at ACC Annual Meeting 2014
GlobeNewswire - Fri Mar 28, 12:42PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR), a biotechnology company focused on developing novel therapeutics to prevent and treat heart disease, today announced Co-founder and Scientific Advisory Board Chairman, Dr. Eduardo Marbán, M.D., Ph.D., will present at the American College of Cardiology 63 Annual Scientific Session and Expo, taking place March 29-31, 2014 in Washington, DC. Dr. Marbán's presentation will highlight positive data demonstrating that the Phase I portion of the Company's ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR) Phase I/II trial met its primary endpoint of safety.
Capricor Therapeutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Mon Mar 10, 1:11PM CDT
Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that Chief Executive Officer Dr. Linda Marbán is scheduled to present at the 26 Annual ROTH Conference, being held March 9-12, 2014 in Dana Point, Calif., and the Alliance for Regenerative Medicine's 2 Annual Regen Med Investor Day on March 26, 2014 in New York, N.Y.
Capricor Therapeutics and Janssen Biotech, Inc. Enter Into Collaboration Agreement and Exclusive License Option
GlobeNewswire - Mon Jan 06, 7:30AM CST
Capricor Therapeutics, Inc. (OTCBB:CAPR) today announced that it has executed a collaboration agreement and exclusive license option with Janssen Biotech, Inc. (Janssen). Under the terms of the agreement, Capricor and Janssen agreed to collaborate on the development of Capricor's cell therapy program for cardiovascular applications, including its lead product, CAP-1002. CAP-1002 is an allogeneic cardiosphere-derived cell (CDC) therapeutic under evaluation in patients who have suffered a large myocardial infarction. Pursuant to the agreement, Capricor and Janssen will collaborate on elements of cell manufacturing development. Capricor will contribute to the costs of the manufacturing collaboration, and will receive an upfront payment of $12.5 million from Janssen.
Capricor Therapeutics Announces Ticker Symbol Change to CAPR
Business Wire - Fri Dec 20, 5:00AM CST
Capricor Therapeutics, Inc. (OTCBB: CAPR), a diversified heart failure biotechnology company, today announced that, effective today, the Company's common stock commences trading on the OTC Markets under the new symbol "CAPR." The previous trading symbol was "NLTXD." The ticker symbol change follows the recently completed merger between Capricor, Inc. and Nile Therapeutics, Inc.